PD-L1/PD1 Modulation Mechanisms in Lung Cancer: From Basic to Translational Evidences
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 August 2020) | Viewed by 58855
Special Issue Editors
Interests: lung cancer; target therapies; precision medicine; resistance mechanisms to target therapies; gene rearrangements; point mutations; next generation sequencing; methylation
Interests: predictive molecular pathology in solid tumors; next generation technologies in molecular biology; liquid biopsies; predictive oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Despite all recent efforts, the complex and dynamic interactions between immune systems and tumors allow us to understand why predicting the response of immune checkpoint inhibitors (ICIs) treatment using a single biomarker might not be possible in lung cancer. The predictive and prognostic values of the PD-L1 expression alone in lung cancer patients is currently under debate because of the methodological assessment of the PD-L1 expression and its temporal variations. Better detailed studies aimed at understanding the molecular basis of the main immunotherapy biomarkers are in demand. Genetic and epigenetic alterations strictly linked to the CD274/PD-L1 and CD279/PD-1 gene modulations have received surprisingly little attention until now, even if the results are currently highlighting the power of this analysis.
In this Special Issue, we plan to focus on genetic and epigenetic alterations that have a significant impact on the PD-L1/PD-1 system in solid tumors. We will discuss their biologic mechanism, detection methodologies, their impact on patients’ outcomes and utility in the context of immunotherapy in the cancer scenario.
Dr. Lucia Anna Muscarella
Dr. Umberto Malapelle
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- predictive molecular pathology
- CD274/PD-L1
- CD279/PD-1
- genomic aberrations
- polymorphisms
- epigenetic modulation
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.